SIRPA and neoplasm: These tumor cells engage the SIRPα-CD47 axis to inhibit antigen-presenting cell phagocytosis, while glycolytic metabolites polarize TAMs toward M2 phenotypes, which secrete IL-10 to dampen immune responses.